FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578758897> ?p ?o ?g. }

• W2578758897 abstract "Abstract Introduction: Successful treatment of AML remains dependent upon cytotoxic chemotherapy. However, traditional regimens are not well tolerated by older patients who are at highest risk of disease, and salvage rates after relapse are low, necessitating novel therapeutic strategies. Our groups identified Wee1 as a potential therapeutic target in AML, particularly in the context of concomitant treatment with cytarabine (Tibes et al, Blood, 2012; Porter et al, Leukemia, 2012). Wee1 inhibits CDK1&2 via phosphorylation thereby stalling cell cycle progression. One consequence of Wee1 inhibition/CDK1 activation is impairment of DNA repair via homologous recombination (Krajewska et al, Oncogene, 2013). Cells in which HR is impaired are dependent upon Parp1/2 function, and HR deficient cells are particularly sensitive to Parp1/2 inhibition. Therefore, we hypothesized that combined Wee1 and Parp1/2 inhibition may result in greater inhibition of AML cell proliferation and survival than either alone. Methods: Human AML cell lines, MV4-11 and Molm-13, and a mouse AML that expresses MLL-ENL/FLT3-ITD were cultured with various concentrations of a Wee1 inhibitor (AZ1775) and a Parp1/2 inhibitor (olaparib) and counted 72 hours later by propidium iodide exclusion and flow cytometry. In some experiments, cells were split into fresh media to recover for 72 more hours. Combination Index (CI) values were calculated by the method of Chou and Talalay. Apoptosis was measured using Annexin V/7AAD and flow cytometry. Western blots were used to confirm inhibition of CDK1/2 phosphorylation and to measure DNA damage induction (gamma-H2AX). Results: Combined inhibition of Wee1 and Parp1/2 was synergistic, as measured by cell numbers at 72 hours, in all 3 cell lines tested, with combination index values ranging from 0.3 to 0.9. When cells were allowed to recover after treatment, those treated by single agents were able to continue proliferating. However, those treated with the combination did not recover as well or at all, indicating greatly impaired proliferative capacity. Combined inhibition of Wee1 and Parp1/2 also resulted in a significant increase in apoptosis greater than either drug alone. Western blots for gamma-H2AX confirmed that the combination of Wee1 and Parp1/2 resulted in more DNA damage than either drug alone. Discussion: Combined inhibition of Wee1 and Parp1/2 results in greater inhibition of AML cell proliferation, DNA damage and apoptosis than either drug alone. Future studies will include experiments with primary patient samples, as well as in vivo trials combining Wee1 inhibition with Parp1/2 inhibition. These preliminary studies raise the possibility of rational combinations of targeted agents for leukemia in those for whom conventional chemotherapeutics may not be well tolerated. Disclosures No relevant conflicts of interest to declare." @default.
• W2578758897 created "2017-01-26" @default.
• W2578758897 creator A5018041025 @default.
• W2578758897 creator A5061818321 @default.
• W2578758897 creator A5063321500 @default.
• W2578758897 creator A5067520350 @default.
• W2578758897 date "2014-12-06" @default.
• W2578758897 modified "2023-09-28" @default.
• W2578758897 title "Combined Inhibition of Wee1 and Poly(ADP Ribose) Polymerase1/2 Synergistically Inhibits Acute Myeloid Leukemia Cells By Enhancing DNA Damage and the Induction of Apoptosis" @default.
• W2578758897 doi "https://doi.org/10.1182/blood.v124.21.3621.3621" @default.
• W2578758897 hasPublicationYear "2014" @default.
• W2578758897 type Work @default.
• W2578758897 sameAs 2578758897 @default.
• W2578758897 citedByCount "1" @default.
• W2578758897 countsByYear W25787588972017 @default.
• W2578758897 crossrefType "journal-article" @default.
• W2578758897 hasAuthorship W2578758897A5018041025 @default.
• W2578758897 hasAuthorship W2578758897A5061818321 @default.
• W2578758897 hasAuthorship W2578758897A5063321500 @default.
• W2578758897 hasAuthorship W2578758897A5067520350 @default.
• W2578758897 hasConcept C120504264 @default.
• W2578758897 hasConcept C151730666 @default.
• W2578758897 hasConcept C153911025 @default.
• W2578758897 hasConcept C182979987 @default.
• W2578758897 hasConcept C190283241 @default.
• W2578758897 hasConcept C203014093 @default.
• W2578758897 hasConcept C2775934118 @default.
• W2578758897 hasConcept C2778041864 @default.
• W2578758897 hasConcept C2778480876 @default.
• W2578758897 hasConcept C2778729363 @default.
• W2578758897 hasConcept C2779343474 @default.
• W2578758897 hasConcept C2779962180 @default.
• W2578758897 hasConcept C2781252693 @default.
• W2578758897 hasConcept C29537977 @default.
• W2578758897 hasConcept C31573885 @default.
• W2578758897 hasConcept C502942594 @default.
• W2578758897 hasConcept C552990157 @default.
• W2578758897 hasConcept C553184892 @default.
• W2578758897 hasConcept C55493867 @default.
• W2578758897 hasConcept C82381507 @default.
• W2578758897 hasConcept C86803240 @default.
• W2578758897 hasConcept C98274493 @default.
• W2578758897 hasConceptScore W2578758897C120504264 @default.
• W2578758897 hasConceptScore W2578758897C151730666 @default.
• W2578758897 hasConceptScore W2578758897C153911025 @default.
• W2578758897 hasConceptScore W2578758897C182979987 @default.
• W2578758897 hasConceptScore W2578758897C190283241 @default.
• W2578758897 hasConceptScore W2578758897C203014093 @default.
• W2578758897 hasConceptScore W2578758897C2775934118 @default.
• W2578758897 hasConceptScore W2578758897C2778041864 @default.
• W2578758897 hasConceptScore W2578758897C2778480876 @default.
• W2578758897 hasConceptScore W2578758897C2778729363 @default.
• W2578758897 hasConceptScore W2578758897C2779343474 @default.
• W2578758897 hasConceptScore W2578758897C2779962180 @default.
• W2578758897 hasConceptScore W2578758897C2781252693 @default.
• W2578758897 hasConceptScore W2578758897C29537977 @default.
• W2578758897 hasConceptScore W2578758897C31573885 @default.
• W2578758897 hasConceptScore W2578758897C502942594 @default.
• W2578758897 hasConceptScore W2578758897C552990157 @default.
• W2578758897 hasConceptScore W2578758897C553184892 @default.
• W2578758897 hasConceptScore W2578758897C55493867 @default.
• W2578758897 hasConceptScore W2578758897C82381507 @default.
• W2578758897 hasConceptScore W2578758897C86803240 @default.
• W2578758897 hasConceptScore W2578758897C98274493 @default.
• W2578758897 hasLocation W25787588971 @default.
• W2578758897 hasOpenAccess W2578758897 @default.
• W2578758897 hasPrimaryLocation W25787588971 @default.
• W2578758897 hasRelatedWork W1983139523 @default.
• W2578758897 hasRelatedWork W2016058914 @default.
• W2578758897 hasRelatedWork W2072062775 @default.
• W2578758897 hasRelatedWork W2317240129 @default.
• W2578758897 hasRelatedWork W2319283415 @default.
• W2578758897 hasRelatedWork W2320105603 @default.
• W2578758897 hasRelatedWork W2505100803 @default.
• W2578758897 hasRelatedWork W2555354504 @default.
• W2578758897 hasRelatedWork W2558250642 @default.
• W2578758897 hasRelatedWork W2563594937 @default.
• W2578758897 hasRelatedWork W2628237747 @default.
• W2578758897 hasRelatedWork W2886600843 @default.
• W2578758897 hasRelatedWork W2911568111 @default.
• W2578758897 hasRelatedWork W2929688087 @default.
• W2578758897 hasRelatedWork W2937914714 @default.
• W2578758897 hasRelatedWork W2979444547 @default.
• W2578758897 hasRelatedWork W2979742153 @default.
• W2578758897 hasRelatedWork W2981375243 @default.
• W2578758897 hasRelatedWork W2984681309 @default.
• W2578758897 hasRelatedWork W3209687653 @default.
• W2578758897 isParatext "false" @default.
• W2578758897 isRetracted "false" @default.
• W2578758897 magId "2578758897" @default.
• W2578758897 workType "article" @default.